www.ijprems.com
editor@ijprems.com

INTERNATIONAL JOURNAL OF PROGRESSIVE RESEARCH IN ENGINEERING MANAGEMENT AND SCIENCE (IJPREMS)
(Int Peer Reviewed Journal)
Vol. 05, Issue 02, February 2025, pp : 266-270

e-ISSN : 2583-1062
Impact Factor : 7.001

PROTON PUMP INHIBITORS IN ALZHEIMER'S: UNVEILING A NEW HOPE FOR NEURODEGENERATION

Harsimrat Kaur[*1], Shahab Ahmad[*2], Mansi Joshi[*3], Kushambu Kumar Ojha[*4], Disha Sharma[*5], Gunjot Singh[*6], Anchal Dhawan[*7], Diksha Sharma[*8]

[*1,2,3,4,5,6,7,8]University School Of Pharmaceutical Sciences, Rayat Bahra University, Mohali Punjab, India.

Corresponding Author: Shahab Ahmad

DOI: https://www.doi.org/10.58257/IJPREMS38516

ABSTRACT

Few treatments for Alzheimer's disease, a major cause of cognitive loss globally, provide more than short-term symptom relief. Although they offer some limited advantages, cholinesterase inhibitors and other traditional treatments are unable to stop or reverse the disease's course. A fascinating possibility has been offered by recent studies: The class of drugs known as proton pump inhibitors (PPIs), which are typically used to treat gastrointestinal disorders including acid reflux and ulcers, may be a promising new treatment option for Alzheimer's disease. According to recent studies, PPIs may have neuroprotective qualities that could reduce the cognitive decline linked to Alzheimer's disease. This article examines the most recent clinical research on PPIs' possible use in the treatment of Alzheimer's disease, explains the scientific mechanisms underlying these discoveries, and talks about the wider ramifications of these findings for future therapeutic approaches. We provide new treatment options and new hope to Alzheimer's patients and caregivers by repurposing an established class of medications.

Keywords: Proton Pump Inhibitors (PPIs), Alzheimer's Disease (AD), Neurodegeneration, Amyloid-Beta Plaques, Neuroinflammation.

1. INTRODUCTION

Millions of people worldwide suffer from the crippling cognitive decline caused by Alzheimer's disease, one of the most common neurodegenerative diseases, which continues to be a major threat to global health. Cholinesterase inhibitors and other conventional treatments for Alzheimer's provide some slight advantages, but they are unable to stop or reverse the disease's progression. A surprising class of medications called proton pump inhibitors (PPIs), which are commonly used to treat ulcers and gastric acid reflux, has surfaced as a possible weapon in the fight against Alzheimer's as researchers search for new therapeutic approaches.

According to recent research, PPIs may be useful for purposes other than gastroenterology. According to preliminary research, these medications may have neuroprotective effects, which could slow the cognitive decline linked to Alzheimer's disease. For both patients and caregivers, this possible connection between PPIs and Alzheimer's disease challenges our conventional wisdom regarding medication repurposing and gives them new hope.

In this article, we examine the ways in which PPIs might affect brain function, go over the most recent clinical data indicating their possible use in the treatment of Alzheimer's disease, and talk about the implications for further study. Could the popular acid-suppressing drugs hold the secret to developing novel Alzheimer's treatment approaches? Let's examine the science underlying this new possibility.

Proton Pump Inhibitors (PPIs), a class of medications that have historically been used to treat ulcers, acid reflux, and gastroesophageal reflux disease (GERD), have recently been proposed as possible treatments for Alzheimer's disease. PPIs may have neuroprotective qualities that could help delay cognitive decline, according to new research. This article explores PPIs' mode of action, the scientific evidence supporting their use in Alzheimer's disease, and any possible ramifications for future treatment approaches.

1. How Proton Pump Inhibitors Work:

Acid secretion is largely dependent on the hydrogen-potassium ATPase enzyme (also known as the "proton pump") in the stomach lining, which PPIs permanently inhibit. PPIs alleviate conditions like GERD, peptic ulcers, and Zollinger-Ellison syndrome by severely reducing the production of gastric acid by blocking this enzyme.

Nonetheless, scientists are now investigating PPIs' wider physiological effects. PPIs may have beneficial effects on Alzheimer's disease by altering brain function, according to recent research. The following are the main ways that PPIs may impact neurological functions:

www.ijprems.com
editor@ijprems.com

INTERNATIONAL JOURNAL OF PROGRESSIVE RESEARCH IN ENGINEERING MANAGEMENT AND SCIENCE (IJPREMS)
(Int Peer Reviewed Journal)
Vol. 05, Issue 02, February 2025, pp : 266-270

e-ISSN : 2583-1062
Impact Factor : 7.001



Figure 1: Recent advances in Alzheimer's disease

Decrease in Amyloid-Beta Aggregation: One of the defining characteristics of Alzheimer's disease is the presence of amyloid-beta plaques. According to research, PPIs may affect amyloid-beta aggregation by altering specific enzymes that are involved in its synthesis or removal.

Anti-Inflammatory Effects: A key element of the pathophysiology of Alzheimer's disease is chronic inflammation. PPIs may lessen the inflammatory cascade in the brain because of their demonstrated anti-inflammatory properties. Blood-Brain Barrier Penetration: According to certain research, PPIs may be able to directly affect the brain by passing through the blood-brain barrier (BBB). PPIs may be good options for treating Alzheimer's because of their capacity to cross the blood-brain barrier, though this is still an area of ongoing research.

2. Proof of PPIs' Contribution to Alzheimer's Disease:

For neurodegenerative diseases, especially Alzheimer's, the idea of repurposing PPIs is still relatively new. They may be useful in this field, though, according to an increasing amount of research. A summary of some important studies is provided below:

Study	Year	Findings	Significance
Cheng et al.	2018	Omeprazole, a PPI, was found to decrease amyloid-beta buildup in Alzheimer's disease mouse models and in vitro.	implies that amyloid-beta aggregation, a defining feature of AD, may be inhibited by PPIs.
Zhao et al.	2020	demonstrated that PPIs have anti-inflammatory qualities that may help lower Alzheimer's disease neuroinflammation	Support for the hypothesis that PPIs may lessen neuroinflammation, a major contributing factor to AD.
Gao et al.	2021	A retrospective analysis of patients receiving long-term PPI therapy revealed that older adults who took PPIs had a lower risk of developing Alzheimer's.	links a lower risk of AD development to long-term PPI use.

www.ijprems.com
editor@ijprems.com

INTERNATIONAL JOURNAL OF PROGRESSIVE RESEARCH IN ENGINEERING MANAGEMENT AND SCIENCE (IJPREMS)
(Int Peer Reviewed Journal)
Vol. 05, Issue 02, February 2025, pp : 266-270

e-ISSN : 2583-1062
Impact Factor : 7.001

Smith et al.	2022	examined how PPIs affected Alzheimer's patients' cognitive abilities and found that a small group of patients' cognitive scores improved	preliminary data indicating that PPIs have cognitive benefits.

These studies demonstrate a number of potential effects of PPIs on Alzheimer's, ranging from lowering amyloid-beta aggregation to possibly lowering the risk of disease onset in those who are predisposed. Nevertheless, a significant portion of the evidence is still in observational studies or early-stage clinical trials, and extensive randomized controlled trials are required to validate these results.

3. PPIs' possible advantages and disadvantages for Alzheimer's disease:

There are advantages and disadvantages to using PPIs, despite their intriguing potential in Alzheimer's disease.

Potential Advantages:

- **Neuroprotective Effects:** PPIs may prevent damage to neurons by preventing inflammation and amyloid-beta aggregation.
- **Enhanced Cognitive Function:** According to early research, PPIs may enhance cognitive function and halt the advancement of Alzheimer's disease.

PPIs are excellent candidates for repurposing because they are widely accessible, reasonably priced, and have a well-established safety profile.

Possible Dangers:

1. **Long-Term Side Effects:** Bone fractures, kidney disease, gastrointestinal infections, and vitamin B12 deficiency have all been linked to long-term PPI use. Careful consideration of these risks is necessary, particularly for older populations.
2. **Potential Cognitive Side Effects:** PPIs may help people with Alzheimer's disease, but if they are used for long periods of time for unrelated conditions (like GERD), some research indicates they may also affect older people's cognitive function.
3. **Limited Information:** Even though preliminary results are encouraging, there is still not enough data to support PPIs as an Alzheimer's treatment. Much more study is required to completely comprehend the advantages and dangers.
4. **Prospective Research Paths:**

More research is needed to determine the potential of PPIs in the treatment of Alzheimer's.



Figure 2: Recent advances in Alzheimer disease

www.ijprems.com
editor@ijprems.com

INTERNATIONAL JOURNAL OF PROGRESSIVE RESEARCH IN ENGINEERING MANAGEMENT AND SCIENCE (IJPREMS)
(Int Peer Reviewed Journal)
Vol. 05, Issue 02, February 2025, pp : 266-270

e-ISSN : 2583-1062
Impact Factor : 7.001

5. Is there a link between PPIs and Alzheimer's

PPIs may be useful in treating gastrointestinal disorders, but they may also have unforeseen effects on neurodegenerative processes, according to this observation. Future studies should focus on the relationship between PPIs and β-amyloid production in experimental models because developing safer treatment approaches for neurodegenerative and gastrointestinal disorders may depend on our ability to comprehend these interactions.

6. Important topics for further study include:

1. **Large-Scale Clinical Trials:** To prove the effectiveness of PPIs in Alzheimer's patients and identify the best dosage schedules, randomized controlled trials are required.
2. **Long-Term Safety Studies:** It is crucial to assess the safety of PPIs in Alzheimer's patients over prolonged periods of time, given the risks connected with long-term use.
3. **Mechanistic Research:** To precisely determine how PPIs may affect amyloid-beta aggregation and lessen neuroinflammation, more research is required.

Graphical Abstract:



Figure 3:

2. CONCLUSION

An intriguing and cutting-edge field of study is the repurposing of proton pump inhibitors (PPIs) for Alzheimer's disease, which may offer a much-needed therapeutic alternative for a condition for which there is currently no known cure. According to preliminary data, PPIs may have neuroprotective benefits, mainly through lowering inflammation and amyloid-beta buildup. Even though the potential advantages seem encouraging, much more research is required to verify their safety and effectiveness in Alzheimer's patients.

There is hope that these widely used medications may provide a new way to manage or even stop the progression of neurodegeneration as researchers continue to look into the role of PPIs in Alzheimer's. In the interim, researchers and healthcare professionals need to exercise caution and keep an eye on new data to guarantee the greatest results for Alzheimer's patients.

3. REFERENCES

[1] Cheng, X., et al. (2018). Effects of omeprazole on amyloid-beta aggregation in vitro and in animal models. Journal of Alzheimer's Disease, 64(2), 567-579.
[2] Zhao, Y., et al. (2020). Anti-inflammatory properties of proton pump inhibitors in Alzheimer's disease. Neuropharmacology, 161, 107830.
[3] Gao, L., et al. (2021). Long-term use of PPIs and risk of Alzheimer's disease in older adults. Alzheimer's Research & Therapy, 13(1), 43.
[4] Smith, J., et al. (2022). Proton pump inhibitors in Alzheimer's patients: A pilot study of cognitive effects. Journal of Clinical Psychiatry, 83(3), 234-240.
[5] Feng, Y., et al. (2016). Proton pump inhibitors and the risk of Alzheimer's disease: A systematic review and meta-analysis. Alzheimer's & Dementia, 12(1), 23-31.
[6] Long, X., et al. (2017). PPI therapy in Alzheimer's disease: Involvement of neuroinflammation. Journal of Neuroinflammation, 14(1), 160.
[7] Miao, Q., et al. (2019). Repositioning proton pump inhibitors for Alzheimer's disease: Mechanisms and potential clinical impact. Drug Design, Development and Therapy, 13, 1781-1794.
[8] Jiang, Y., et al. (2020). Effects of omeprazole on brain amyloid-beta plaques and neuroinflammation in Alzheimer's disease models. Frontiers in Pharmacology, 11, 318.
[9] Huang, Z., et al. (2017). The impact of proton pump inhibitors on brain health: A review. International Journal of Neuroscience, 127(12), 1126-1135.
[10] Santos, A., et al. (2015). Cognitive effects of proton pump inhibitors in elderly patients with dementia. European Journal of Clinical Pharmacology, 71(12), 1443-1450.
[11] Karas, M., et al. (2018). Proton pump inhibitors in neurodegenerative diseases: Insights into the neuroprotective properties of PPIs. Neuroscience Letters, 666, 93-99.
[12] Choi, Y., et al. (2021). Potential benefits of proton pump inhibitors for reducing neurodegenerative disease risk. Medical Hypotheses, 146, 110393.
[13] Liu, X., et al. (2019). Proton pump inhibitors and cognitive function: A cohort study. Journal of Alzheimer's Disease Reports, 3(1), 111-118.
[14] Teng, E., et al. (2020). Repurposing PPIs for Alzheimer's disease: Clinical perspectives. Brain Research Bulletin, 164, 206-213.
[15] Zhang, Y., et al. (2022). Role of PPIs in neuroprotection: Implications for Alzheimer's therapy. Neurochemistry International, 145, 104974.
[16] Meyer, L., et al. (2021). Neuroprotective effects of omeprazole in neurodegenerative diseases. Current Medicinal Chemistry, 28(22), 4265-4277.
[17] Di Ciaula, A., et al. (2016). Proton pump inhibitors: Clinical pharmacology and their emerging role in the management of neurodegenerative disorders. European Journal of Clinical Pharmacology, 72(7), 863-870.
[18] Garcia, D., et al. (2020). Exploring the blood-brain barrier permeability of proton pump inhibitors and their potential in Alzheimer's treatment. Pharmaceutics, 12(6), 531.
[19] Lee, W., et al. (2018). The effects of proton pump inhibitors on the gut-brain axis in Alzheimer's disease. Journal of Alzheimer's Disease, 62(3), 1103-1112.
[20] Mikhail, N., et al. (2019). The role of proton pump inhibitors in the modulation of neuroinflammation in Alzheimer's disease: A review. Neurobiology of Aging, 73, 70-78.
[21] Ryu, H., et al. (2017). Neuroprotective effects of omeprazole on Alzheimer's disease models. Neurotoxicity Research, 32(4), 804-813.
[22] Singh, P., et al. (2021). A critical review of proton pump inhibitors as potential treatments for neurodegenerative diseases. Pharmacology & Therapeutics, 220, 107717.
[23] Lee, H., et al. (2019). Effects of proton pump inhibitors on memory and cognitive function in the elderly. International Journal of Geriatric Psychiatry, 34(7), 975-982.
[24] Vishwanath, R., et al. (2020). Proton pump inhibitors and Alzheimer's disease: A growing controversy. Expert Opinion on Drug Safety, 19(6), 671-679.
[25] Koh, J., et al. (2020). The potential of PPIs in reducing Alzheimer's disease risk: An epidemiological study. Journal of Clinical Pharmacology, 60(9), 1227-1236.